Possible Risk Factors for Bone Marrow Fibroplasia in Patients with Polycythemia Vera.
10.19746/j.cnki.issn.1009-2137.2023.06.027
- Author:
De-Hao WANG
1
;
Pei ZHAO
1
;
Zi-Qing WANG
1
;
Er-Peng YANG
2
;
Yu-Meng LI
2
;
Ji-Cong NIU
2
;
Yi CHEN
1
;
Ke CHEN
2
;
Ming-Jing WANG
2
;
Wei-Yi LIU
2
;
Yan LYU
3
;
Xiao-Mei HU
4
Author Information
1. Graduate School of Beijing University of Chinese Medicine, Beijing 100029, China.
2. Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
3. Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China,E-mail: lvyan060809@163.com.
4. Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China,E-mail: huxiaomei_2@163.com.
- Publication Type:Journal Article
- Keywords:
ibrous tissue hyperplasia;
low density lipoprotein;
olycythemia vera;
one marrow biopsy;
osinophils
- MeSH:
Humans;
Bone Marrow/pathology*;
Polycythemia Vera;
Hyperplasia/pathology*;
Granulocytes/pathology*;
Janus Kinase 2/genetics*;
Risk Factors;
Lipoproteins, LDL;
Polycythemia/pathology*
- From:
Journal of Experimental Hematology
2023;31(6):1780-1786
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To understand the biological characteristics of polycythemia vera (PV) patients with myeloid fibroplasia, and further analyze the risk factors affecting myeloid fibroplasia in PV patients, so as to provide ideas for predicting the occurrence of myeloid fibroplasia in PV patients.
METHODS:Forty patients with PV in the Department of Hematology, Xiyuan Hospital of China Academy of Chinese Medical Sciences were collected and divided into two groups, with (hyperplasia group) and without (Non-proliferative group) hyperplasia of bone marrow fibers. The differences of basic clinical characteristics, blood routine, biochemistry, bone marrow cells, coagulation function and other indicators between the two groups were compared, and the independent risk factors affecting the proliferation of bone marrow fibrous tissue in PV patients were further analyzed by multivariate regression.
RESULTS:Compared with Non-proliferative group, the JAK2 mutation rate (95% vs 70%，P=0.037), eosinophilic cell count (0.19 vs 0.11, P=0.047) and eosinophilic percentage (1.84 vs 1.27, P=0.001) in PV patients with hyperplasia were significantly increased, triglycerides (1.55 vs 1.91, P=0.038) and low-density lipoprotein (1.50 vs 3.08, P=0.000) were significantly reduced, bone marrow hematopoietic volume (0.85 vs 0.6, P=0.001), granulocyte/erythrocyte ratio (3.40 vs 1.89, P=0.033), lymphocyte/erythrocyte ratio (0.60 vs 0.42, P=0.033), and granulocyte+lymphocyte/erythrocyte ratio (3.72 vs 2.37, P=0.026) were significantly increased, thrombin time (18.84 vs 18.12, P=0.043) was significantly prolonged. Multivariate regression analysis results showed that peripheral blood eosinophil ≥2% and low-density lipoprotein ≤2 mmol/L were independent risk factors for bone marrow fibrous tissue hyperplasia in PV patients (P<0.05).
CONCLUSION:Increased proportion of peripheral blood eosinophils and decreased low density lipoprotein are risk factors for bone marrow fibrous tissue hyperplasia in PV patients.
